These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

889 related articles for article (PubMed ID: 10790340)

  • 1. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
    Tanner FC; Boehm M; Akyürek LM; San H; Yang ZY; Tashiro J; Nabel GJ; Nabel EG
    Circulation; 2000 May; 101(17):2022-5. PubMed ID: 10790340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.
    Hsieh FF; Barnett LA; Green WF; Freedman K; Matushansky I; Skoultchi AI; Kelley LL
    Blood; 2000 Oct; 96(8):2746-54. PubMed ID: 11023508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes.
    McConnell BB; Gregory FJ; Stott FJ; Hara E; Peters G
    Mol Cell Biol; 1999 Mar; 19(3):1981-9. PubMed ID: 10022885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors.
    Parry D; Mahony D; Wills K; Lees E
    Mol Cell Biol; 1999 Mar; 19(3):1775-83. PubMed ID: 10022865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery.
    Chen D; Krasinski K; Sylvester A; Chen J; Nisen PD; Andrés V
    J Clin Invest; 1997 May; 99(10):2334-41. PubMed ID: 9153274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted regulation of cell cycle progression by estrogen: regulation of Cdk inhibitors and Cdc25A independent of cyclin D1-Cdk4 function.
    Foster JS; Henley DC; Bukovsky A; Seth P; Wimalasena J
    Mol Cell Biol; 2001 Feb; 21(3):794-810. PubMed ID: 11154267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
    Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
    Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors.
    Salatino M; Labriola L; Schillaci R; Charreau EH; Elizalde PV
    Exp Cell Res; 2001 Apr; 265(1):152-66. PubMed ID: 11281653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
    Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
    Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27.
    Hupfeld CJ; Weiss RH
    Am J Physiol Endocrinol Metab; 2001 Aug; 281(2):E207-16. PubMed ID: 11440895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
    Rao S; Lowe M; Herliczek TW; Keyomarsi K
    Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early G1 growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21[CIP1] induction.
    Ponzio G; Loubat A; Rochet N; Turchi L; Rezzonico R; Farahi Far D; Dulic V; Rossi B
    Oncogene; 1998 Sep; 17(9):1159-66. PubMed ID: 9764826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical examination of the INK4 and Cip inhibitors in the rat neonatal cerebellum: cellular localization and the impact of protein calorie malnutrition.
    Shambaugh GE; Haines GK; Koch A; Lee EJ; Zhou Jn; Pestell R
    Brain Res; 2000 Feb; 855(1):11-22. PubMed ID: 10650125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells.
    Hsu SL; Hsu JW; Liu MC; Chen LY; Chang CD
    Exp Cell Res; 2000 Aug; 258(2):322-31. PubMed ID: 10896783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle.
    Bresnahan WA; Boldogh I; Ma T; Albrecht T; Thompson EA
    Cell Growth Differ; 1996 Oct; 7(10):1283-90. PubMed ID: 8891332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1).
    Marra DE; Simoncini T; Liao JK
    Circulation; 2000 Oct; 102(17):2124-30. PubMed ID: 11044431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).
    Depoortere F; Pirson I; Bartek J; Dumont JE; Roger PP
    Mol Biol Cell; 2000 Mar; 11(3):1061-76. PubMed ID: 10712520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a p23 caspase-cleaved form of p27[KIP1] involved in G1 growth arrest.
    Loubat A; Rochet N; Turchi L; Rezzonico R; Far DF; Auberger P; Rossi B; Ponzio G
    Oncogene; 1999 Jun; 18(22):3324-33. PubMed ID: 10362353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of cyclin-dependent kinase inhibitors in vascular disease.
    Tanner FC; Yang ZY; Duckers E; Gordon D; Nabel GJ; Nabel EG
    Circ Res; 1998 Feb; 82(3):396-403. PubMed ID: 9486668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.